Name: 潰瘍性大腸炎-結腸直腸癌(UC-CRC)モデルの評価とLiujunzi煎じ薬(LJZD)の有効性
Uploaded: 2023-10-13T12:50:00
Description: Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

evaluation of an ulcerative coloproctitis-colorectal cancer (uc-crc) model and efficacy of liujunzi decoction (ljzd)

Liujunzi煎じ薬:UC-CRC予防のための効果的な治療法

Colorectal cancer (CRC) is a common gastrointestinal malignancy, the third most common malignancy, and the second most common cause of death in the world, accounting for 10% of the global cancer incidence and 9.4% of the total cancer-related death1,2. Genetic factors, chronic inflammation, high-fat diet, diabetes, and abnormal intestinal flora are risk factors for CRC3,4. Among them, inflammatory bowel disease, especially ulcerative coloproctitis (UC), is a clear risk factor for CRC5,6. UC-associated CRC (UC-CRC) is a transition process of inflammation, atypical hyperplasia, and cancer based on chronic inflammation of the colorectum, which is different from the typical adenoma-adenocarcinoma development model of CRC7,8. Compared with the general population, the risk of CRC is approximately 10-40 times higher in patients with inflammatory bowel disease9.
Currently, surgery is still the standard treatment for CRC, and depending on the location and stage of the tumor, radiation therapy, systemic drug therapy, or a combination of both are possible10. Although these traditional treatment modalities have made great progress, due to the high heterogeneity and recurrence rate of CRC, the prognosis is poor, and the treatment effect is not ideal11,12. Therefore, early detection, early diagnosis, and comprehensive treatment are key to improving the survival rate of CRC patients, and it is particularly important to pay attention to the transformation of UC to CRC. Over the years, traditional Chinese medicine (TCM) has attracted much attention in the treatment of UC-CRC or chronic gastritis due to its limited side effects and significant efficacy. Based on dialectical treatment, famous Chinese medicine practitioners of various generations have created a large number of classic prescriptions, such as Huangqi Jianzhong decoction13, Sijunzi decoction14, and Sishen pill15.
Liujunzi decoction (LJZD) originated from the works of Yi Xue Zheng Zhuan compiled in the Ming Dynasty and is a classic prescription in TCM16. As shown in Table 1, LJZD consists of six traditional herbs, including Codonopsis pilosula (Franch.) Nannf. (Dangshen), Poria cocos (Schw.) Wolf (Fuling), Atractylodes macrocephala Koidz. (Baizhu), Glycyrrhiza uralensis Fisch. (Gancao), Citrus reticulata Blanco (Chenpi) and Pinellia ternata (Thunb.) Breit (Banxia), which has the effect of replenishing qi and strengthening the spleen, drying dampness, and resolving phlegm. In modern clinical practice, it is often used to treat chronic gastritis, gastric ulcers, and duodenal ulcers. Modern pharmacological research has shown that LJZD and modified LJZD have high application value in the adjuvant treatment of UC and digestive tract cancer17,18,19.
At present, there are many ways to construct UC-CRC mouse models, but the azoxymethane (AOM)/dextran sulfate sodium (DSS) induced mouse model is the most widely used UC-CRC model; the clinical symptoms, morphological, and pathological observations have proved that the model is very similar to human UC-CRC20,21. The basic principle is to first induce carcinogenesis with chemical carcinogen AOM and then continuously expose mice to the inflammatory stimulation environment of DSS to simulate the continuous damage and repair of intestinal mucosal epithelium, thereby constructing a UC-CRC mouse model22. The aim of this study is to establish a mouse model of UC-CRC by intraperitoneal injection of AOM and cyclic stimulation of DSS in the short term and to evaluate the effect of the drug and the molecular mechanism of LJZD on UC-CRC in order to provide a scientific basis for the treatment of UC-CRC.

著者スポットライト:大腸がんに対する伝統的な中国の治療法としてのLiujunzi煎じ薬

マウスにおける大腸肛門炎モデルの設定と漢方薬の治療効果評価

This study was on the prevention and treatment of coloproctitis cancer with traditional Chinese medicine. We aim to establish a mouse model for coloproctitis cancer and evaluate traditional Chinese medicine indicators. We confirmed that the Chinese medicine Liujunzi decoction is a effective treatment for coloproctitis cancer prevention.In the future, we will work to identify more sensitive biomarkers for colon and rectal cancer and screen Liujunzi decoction for therapeutic targets.

Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

潰瘍性大腸炎-結腸直腸癌(UC-CRC)モデルの評価とLiujunzi煎じ薬(LJZD)の有効性

まず、UC-CRCマウスモデルを確立し、調製したLJZDおよび5-ASA溶液をそれぞれのグループに投与します。薬物治療後、適応摂食の開始から薬物治療の終了まで、マウスの体重を毎日監視します。各実験マウスの糞便の粘稠度を注意深く観察し、記録し、正常、軟便、または水様性下痢に分類します。実験動物で観察された糞便出血を注意深く記録し、出血なし、最小限の出血、または便中の目に見える血液に分類します。結腸直腸組織を分離するには、安楽死させたマウスを極低温解剖学的環境内に維持します。マウスを仰臥位で固定します。ハサミを使用して、下腹部の毛を刈り取り、エタノールでその部分を殺菌します。まぶたの鉗子を使用して、2つの大腿根と腹部正中線の交点をそっとつかみます。次に、ハサミを使用して、長さ1〜1.5センチの横切開を作成します。横切開の中間点から剣状突起まで、腹部の正中線に沿って縦方向の切開を行います。大腸周囲組織を肛門に向かって慎重に剥離し、結腸直腸を周囲の組織から分離します。腹部の皮膚をそっと脇に押しのけて、結腸直腸を完全に露出させます。まぶた鉗子を使用して、腹腔から結腸直腸を抽出し、肛門から盲腸まで切片化します。採取した結腸直腸組織を摂氏4度の生理食塩水で保存します。UC-CRCモデル群は、LJZD治療によって緩和された対照群と比較して有意な体重減少を示しました。LJZD治療は、UC-CRCモデル群と比較して疾患活動性指数を改善した。

Research

JoVE Journal

Medicine

Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer (UC-CRC) Model and Efficacy of Liujunzi Decoction (LJZD)

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Colorectal cancer (CRC) is a common malignancy of the digestive system and has become the third most common malignancy worldwide and the second leading ...